US Stock Alert: SELLAS Life Sciences plummets on November 18 due to $150 million additional issuance and profit-taking at high levels
Bitget异动解读2026/11/18 14:51SELLAS Life Sciences November 18 Sharp Decline Interpretation
Keywords: $150 million additional offering, profit taking at high levels
1. On November 17, the company announced an underwritten public offering of $150 million in common stock and granted underwriters an additional 30-day $22.5 million purchase option. The additional offering led to expectations of equity dilution, putting pressure on the stock price during after-hours and November 18 trading.
2. On November 17, the company announced that its REGAL Phase III trial met its primary endpoint: the median overall survival in the cancer vaccine group was 24.0 months, compared to 14.7 months in the control group, representing a 41% reduction in risk of death. The stock price surged that day; following the additional offering announcement on November 18, the stock price gave back some of its gains.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Swiss franc remains stable after the release of key economic data

The euro holds its gains, while the pound is weighed down by UK inflation data.

GBP/JPY briefly gains support as hawkish tone from Bank of England dominates

The Japanese yen weakens as the Federal Reserve minutes show a hawkish stance
